MQS Management LLC Has $832,000 Stake in AstraZeneca PLC (NASDAQ:AZN)

MQS Management LLC lifted its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 303.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,681 shares of the company's stock after acquiring an additional 8,033 shares during the period. MQS Management LLC's holdings in AstraZeneca were worth $832,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Martin Investment Management LLC grew its position in shares of AstraZeneca by 2.8% during the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company's stock valued at $22,571,000 after acquiring an additional 7,615 shares during the period. Integrated Advisors Network LLC grew its stake in shares of AstraZeneca by 46.6% in the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company's stock worth $3,398,000 after acquiring an additional 13,860 shares in the last quarter. Creative Planning lifted its position in shares of AstraZeneca by 8.0% during the 3rd quarter. Creative Planning now owns 224,751 shares of the company's stock worth $17,510,000 after purchasing an additional 16,692 shares during the last quarter. TD Asset Management Inc lifted its position in AstraZeneca by 8.6% in the first quarter. TD Asset Management Inc now owns 1,537,410 shares of the company's stock valued at $104,160,000 after acquiring an additional 121,876 shares during the last quarter. Finally, Northcape Wealth Management LLC purchased a new stake in AstraZeneca in the second quarter valued at $269,000. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Up 0.2 %

AZN stock traded up $0.10 during mid-day trading on Wednesday, hitting $65.29. 6,421,854 shares of the company were exchanged, compared to its average volume of 5,243,666. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The firm has a market cap of $202.44 billion, a P/E ratio of 31.11, a P/E/G ratio of 1.21 and a beta of 0.47. The firm's 50 day simple moving average is $76.20 and its 200 day simple moving average is $78.47.

Analysts Set New Price Targets

AZN has been the subject of a number of recent analyst reports. TD Cowen raised their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a "buy" rating in a research report on Monday, August 12th. Erste Group Bank raised shares of AstraZeneca from a "hold" rating to a "buy" rating in a research note on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a "sell" rating to a "hold" rating in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.